The content on this site is intended for healthcare professionals only
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
The potential of T-cell engagers in SCLC treatment
Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma
Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer
Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer
Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities
Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations
Cracking the code: Bispecific immunotherapy in small cell lung cancer
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC
Durvalumab after SBRT reduces tumour progression in early-stage NSCLC
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer
